Search Results for: 68

Investors

About Theriva™ Biologics, Inc. Theriva Biologics (NYSE American: TOVX), is a diversified clinical-stage company developing therapeutics designed to treat cancer and related diseases in areas of high unmet need. The Company’s subsidiary Theriva Biologics, S.L. , has been developing a new oncolytic adenovirus platform designed for intravenous (IV), intravitreal and antitumoral delivery to trigger tumor

Investors Read More »

Synthetic Biologics to Host Conference Call and Webcast to Discuss Second Quarter 2022 Operational Highlights and Financial Results

ROCKVILLE, Md., Aug. 04, 2022 (GLOBE NEWSWIRE) — Synthetic Biologics, Inc. (NYSE American: SYN), a diversified clinical-stage company developing therapeutics designed to treat diseases in areas of high unmet need, today announced that it plans to host a conference call on Thursday, August 11, 2022, at 8:30 a.m. ET to discuss its financial results for

Synthetic Biologics to Host Conference Call and Webcast to Discuss Second Quarter 2022 Operational Highlights and Financial Results Read More »

Synthetic Biologics Announces $3 Million Private Placement of Convertible Preferred Stock

ROCKVILLE, Md., July 29, 2022 (GLOBE NEWSWIRE) — Synthetic Biologics, Inc.. (NYSE American: SYN) (“Synthetic Biologics” or the “Company”), a diversified clinical-stage company developing therapeutics designed to treat diseases in areas of high unmet need, today announced the private placement of 275,000 shares of Series C convertible preferred stock and 100,000 shares of Series D

Synthetic Biologics Announces $3 Million Private Placement of Convertible Preferred Stock Read More »

Synthetic Biologics Reports First Quarter 2022 Operational Highlights and Financial Results

-Encouraging data further supports the development of novel oncolytic adenovirus (OV) platform; Announced a peer-reviewed publication highlighting positive clinical data on VCN-01 and an upcoming oral presentation on VCN-11, a novel oncolytic adenovirus designed to evade neutralizing antibodies- – Reported positive safety data on SYN-020 intestinal alkaline phosphatase from the Phase 1 Multiple Ascending Dose

Synthetic Biologics Reports First Quarter 2022 Operational Highlights and Financial Results Read More »

Synthetic Biologics Reports Positive Safety Data on SYN-020 Intestinal Alkaline Phosphatase Phase 1 Multiple Ascending Dose Clinical Trial

-Orally administered SYN-020 observed to be well tolerated across all doses in healthy volunteers- ROCKVILLE, Md., May 10, 2022 (GLOBE NEWSWIRE) — Synthetic Biologics, Inc. (NYSE American: SYN), a diversified clinical-stage company developing therapeutics designed to treat diseases in areas of high unmet need, today announced positive safety data from its Phase 1, placebo-controlled, double-blind

Synthetic Biologics Reports Positive Safety Data on SYN-020 Intestinal Alkaline Phosphatase Phase 1 Multiple Ascending Dose Clinical Trial Read More »

Synthetic Biologics to Host Conference Call and Webcast to Discuss First Quarter 2022 Operational Highlights and Financial Results

ROCKVILLE, Md., May 09, 2022 (GLOBE NEWSWIRE) — Synthetic Biologics, Inc. (NYSE American: SYN), a diversified clinical-stage company developing therapeutics designed to treat diseases in areas of high unmet need, today announced that it plans to host a conference call on Monday, May 16, 2022, at 8:30 a.m. ET to discuss its financial results for

Synthetic Biologics to Host Conference Call and Webcast to Discuss First Quarter 2022 Operational Highlights and Financial Results Read More »